Puma Biotechnology Reports Third Quarter 2021 Financial Results | Business Wire
Do Analysts Expect Puma Biotechnology Inc (PBYI) Stock to Rise After It Is Down -3.83% in a Month?
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Form 8-K PUMA BIOTECHNOLOGY, INC. For: Jan 13
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PBYI Insider Trading - PUMA BIOTECHNOLOGY Inc - SecForm4.Com
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology, Inc. 2020 Q3 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology's (PBYI) Highest Price: $275.07 (on 09-18-2014)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology (PBYI) Company Information - Simply Wall St
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Puma Biotechnology, Inc. 2020 Q3 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2022
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Articles with Puma Biotechnology
Puma Biotechnology
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
